How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Lung Cancer Trials

Select Clinical Trial

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

  • Men or women, ages 18 and older, diagnosed with limited-stage small-cell lung cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

 

SWOG 1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

  • Men or women, ages 18 and older, diagnosed with squamous cell non-small cell lung cancer; disease must be either advanced, stage IIIB or IV. For additional criteria, call our Clinical Trials office at (910) 715-2200.

 

ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

  • Men or women, ages 18 or older, diagnosed with Stage IIIA, II or large IB non-small cell lung cancer (NSCLC).  For additional criteria, call our Clinical Trials Office at (910) 715-2200.

 

Bristol Myers Squib CA 209384/ Lung

  •  Compares Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
  • Patient population: 18 years and older;Squamous or non-Squamous Non-small cell lung cancer

            

  PharmaMar Atlantis/ Lung

  •  Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
  • Patient population: 18 years or older; diagnosis of limited or extensive stage Small Cell Lung Cancer which failed one prior platinum-containing regimen and with a chemotherapy-free interval
Specialties
Clara McLean House
Make a Donation
News & Events